Uniqure NV (NASDAQ:QURE)

26.30
Delayed Data
As of Dec 01
 +0.69 / +2.69%
Today’s Change
12.52
Today|||52-Week Range
30.41
+26.81%
Year-to-Date
Why Shares of uniQure Rose 14.61% on Wednesday
Nov 23 / MotleyFool.com - Paid Partner Content
uniQure (QURE) Partner Gets FDA Nod for Hemophilia B Gene Therapy
Nov 23 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close25.61
Today’s open26.62
Day’s range26.12 - 27.16
Volume18,818
Average volume (3 months)695,058
Market cap$1.3B
Data as of 4:00pm ET, 12/01/2022

Growth & Valuation

Earnings growth (last year)--
Earnings growth (this year)-151.88%
Earnings growth (next 5 years)+2.00%
Revenue growth (last year)+1,296.82%
P/E ratioNM
Price/Sales1.85
Price/Book2.09

Competitors

 Today’s
change
Today’s
% change
TVTXTravere Therapeutics...-0.59-2.93%
NVAXNovavax Inc+0.38+2.30%
IMGNImmunoGen Inc+0.08+1.54%
----
Data as of 4:00pm ET, 12/01/2022

Financials

Next reporting dateMarch 15, 2023
EPS forecast (this quarter)-$0.79
Annual revenue (last year)$524.0M
Annual profit (last year)$329.6M
Net profit margin62.90%

Profile

Sector
Health Technology
Industry
Biotechnology
No executives to display
Corporate headquarters
Amsterdam, Noord-holland

Forecasts